Navigation Links
Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids

y not be consistent with interim data, Repros' ability to obtain regulatory approval and Repros' ability to raise additional capital on acceptable terms or at all, and such other risks which are identified in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, as they may be updated by the Company's Exchange Act filings from time to time. These documents are available on request from Repros Therapeutics or at www.sec.gov. Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact

Repros Therapeutics Inc., The Woodlands
Joseph S. Podolski, 281-719-3447
President & CEO


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
2. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
3. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
4. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
7. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
8. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
9. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
10. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
11. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
Post Your Comments:
(Date:7/1/2015)... 2015  AVACEN, Inc. announced today the issue by the ... medical technology platform supporting its unique Dry Heat Therapy AVACEN ... Logo - http://photos.prnewswire.com/prnh/20150630/227364LOGO ... 9,066,781 - Methods And Apparatus For Therapeutic Application of Thermal ... methods of use, referred to by the company as the ...
(Date:7/1/2015)... 1, 2015 Radiant Insights announce ... Oxygen Concentrators Market Shares, Strategy, and Forecasts, Worldwide, ... continuing growth as the aging population worldwide needs homecare ... conditions where oxygen is able to improve the quality ... have become affordable and support a mobile lifestyle even ...
(Date:7/1/2015)... , July 1, 2015 ... is expected to reach USD 49,119.2 million by 2020, ... Inc. Monitoring services is expected to remain the dominant ... USD 1,227.5 million in 2012, and an estimated CAGR ... (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , Browse full ...
Breaking Medicine Technology:AVACEN Medical Patent Issued 2Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 2Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 3Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 4mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 2mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 3mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 4mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 5
... following statement,by Andrea Kavanagh, Director of the Pure Salmon ... publish a study tomorrow that,shows sea lice from open ... wild fish stocks., "This study confirms what we ... havoc on wild salmon populations. If outbreaks of these,parasites ...
... Results, SOUTH SAN FRANCICSO, Calif., Dec. 13 ... announced that its oral syk,kinase inhibitor, R788 (tamatinib ... Arthritis (RA) patients in a,recently completed Phase 2 ... 150mg po bid (orally, twice daily), showed higher ...
Cached Medicine Technology:Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 2Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 3Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 4Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 5Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 6
(Date:7/1/2015)... ... July 01, 2015 , ... ... software products, announced today that it has received trademark protection for its SensorInsight® ... detailed analysis of data from multiple sources providing an environment where users can ...
(Date:7/1/2015)... ... July 01, 2015 , ... Amada Senior Care, premier provider ... in the greater Phoenix area – their Mesa, Arizona location . Amada franchise ... with their purchase of the rights to the area after years of experience in ...
(Date:7/1/2015)... Bethlehem, PA (PRWEB) , ... July 01, 2015 , ... ... seek meaning and purpose in life with a healthy balance between work and life, ... do this in her new book, Positive Health: Flourishing Lives, Wellbeing in Doctors. , ...
(Date:7/1/2015)... Newport Beach, CA (PRWEB) , ... July 01, ... ... Orrick has returned to the Northbound team as Director of Referral Relations. ... two programs, including Northbound’s Collegebound, where she designed and implemented unique academic curriculum ...
(Date:7/1/2015)... ... July 01, 2015 , ... AvePoint, the ... opening of a new operational office in Zurich, Switzerland. The new facility will ... lines of business for organizations throughout the Swiss market. , “AvePoint is ...
Breaking Medicine News(10 mins):Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 3Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 4Health News:Amada Senior Care Expands to Greater Phoenix Area 2Health News:Medical Doctor Explains The Healthy Effects of a Positive Outlook in New Book 2Health News:Northbound Treatment Services Welcomes Emily Orrick as Director of Referral Relations 2Health News:AvePoint Opens Office in Zurich to Meet Increasing Market Demand for Enterprise Collaboration Solutions in Switzerland 2Health News:AvePoint Opens Office in Zurich to Meet Increasing Market Demand for Enterprise Collaboration Solutions in Switzerland 3
... is a risk factor for breast cancer development. However, ... ,These ER-alphanegative cancers are more aggressive and ... and have been thought to be estrogen independent. ... in advance of publication in the August print issue ...
... of the most renowned church leaders in Lesotho have signed ... the country, the UN Action Against AIDS (UNAIDS) said ... tragic toll of the AIDS epidemic, brings compelling urgency to ... achieve Universal Access for all to HIV prevention, treatment, care ...
... research has found that turning cancer cells into mini ... efficient. ,Researchers from the University of New ... Albuquerque have found that these nanoparticles could make biopsies ... need to repeat these invasive tests. ...
... that surrounds the axons of nerve cells is attacked by ... nerve impulses and, ultimately, axon loss . ,Myelin ... sheath and when used as an antigen will induce experimental ... animal model of human MS. ,Interestingly, myelin-specific T ...
... has developed a drug that is more effective in ... . ,The drug also costs less than ... reported The Himalayan Times daily.Doctors at the Patan Hospital ... ,,The team compared the effectiveness of "Cefixime", ...
... is back to the levels of 20 years ago is ... it once was and homosexuals are consequently less afraid of ... in Melbourne in which a 48-year-old was charged with deliberately ... that something more nefarious is at work. ,,The Age ...
Cached Medicine News:Health News:Senior Church Leaders in Lesotho Pledge to Fight AIDS 2Health News:New Nano-power Could Make Biopsies Sensitive and Efficient 2Health News:Autoimmune Response in Multiple Sclerosis 2
... an OraSure HIV-1 Oral Specimen Collection Device is ... for HIV-1 antibodies. Testing with the OraSure HIV-1 ... needles and has been shown to be more ... specially treated cotton fiber pad attached to a ...
... benefits of TiMAX material have been applied to ... strength and an ultra-low profile combine to provide ... lower extremity. , ,This complete set of periarticular ... , Fibula Composite Plate , ...
The DePuy ACE Titanium Active Compression Plate offers ingenuity in the art of fracture management....
Corneal Marking Pen - Sterile. 10 pieces/box...
Medicine Products: